

Investigation of trimethoprim/sulfamethoxazole resistance in an emerging sequence type 5 methicillin-resistant *Staphylococcus aureus* clone reveals discrepant resistance reporting

Harris, T. M.; Bowen, A. C.; Holt, D. C.; Sarovich, D. S.; Stevens, K.; Currie, B. J.; Howden, B. P.; Carapetis, J. R.; Giffard, P. M.; Tong, S. Y.C.

Published in:
Clinical Microbiology and Infection

DOI:
[10.1016/j.cmi.2018.04.020](https://doi.org/10.1016/j.cmi.2018.04.020)

Published: 01/09/2018

Document Version
Peer reviewed version

[Link to publication](#)

Citation for published version (APA):

Harris, T. M., Bowen, A. C., Holt, D. C., Sarovich, D. S., Stevens, K., Currie, B. J., Howden, B. P., Carapetis, J. R., Giffard, P. M., & Tong, S. Y. C. (2018). Investigation of trimethoprim/sulfamethoxazole resistance in an emerging sequence type 5 methicillin-resistant *Staphylococcus aureus* clone reveals discrepant resistance reporting. *Clinical Microbiology and Infection*, 24(9), 1027-1029. <https://doi.org/10.1016/j.cmi.2018.04.020>

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Accepted Manuscript

Investigation of trimethoprim-sulfamethoxazole resistance in an emerging sequence type 5 methicillin-resistant *Staphylococcus aureus* clone reveals discrepant resistance reporting

T.M. Harris, A.C. Bowen, D.C. Holt, D.S. Sarovich, K. Stevens, B.J. Currie, B.P. Howden, J.R. Carapetis, P.M. Giffard, S.Y.C. Tong

PII: S1198-743X(18)30360-4

DOI: [10.1016/j.cmi.2018.04.020](https://doi.org/10.1016/j.cmi.2018.04.020)

Reference: CMI 1298

To appear in: *Clinical Microbiology and Infection*


Received Date: 4 December 2017

Revised Date: 12 April 2018

Accepted Date: 22 April 2018

Please cite this article as: Harris TM, Bowen AC, Holt DC, Sarovich DS, Stevens K, Currie BJ, Howden BP, Carapetis JR, Giffard PM, Tong SYC, Investigation of trimethoprim-sulfamethoxazole resistance in an emerging sequence type 5 methicillin-resistant *Staphylococcus aureus* clone reveals discrepant resistance reporting, *Clinical Microbiology and Infection* (2018), doi: 10.1016/j.cmi.2018.04.020.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 Article Type: Letter

2 Investigation of trimethoprim-sulfamethoxazole resistance in an emerging sequence
3 type 5 methicillin-resistant *Staphylococcus aureus* clone reveals discrepant resistance
4 reporting

5 T.M. Harris^a, A.C. Bowen^{a,b,c}, D.C. Holt^{a,d}, D.S. Sarovich^{a,e}, K. Stevens^f, B.J. Currie^a, B.P.

6 Howden^f, J.R. Carapetis^{b,c}, P.M. Giffard^{a,d}, S.Y.C. Tong^{a,g}

7 Menzies School of Health Research, Darwin, Northern Territory, Australia^a; Princess Margaret
8 Hospital for Children, Perth, Western Australia, Australia^b; Wesfarmers Centre for Vaccines and
9 Infectious Diseases, Telethon Kids Institute, University of Western Australia, Perth, Western
10 Australia, Australia^c; School of Health and Human Sciences, Charles Darwin University, Darwin,
11 Northern Territory, Australia^d; Faculty of Science, Health, Education and Engineering, University
12 of the Sunshine Coast, Sippy Downs, Queensland, Australia^e; Microbiological Diagnostic Unit
13 Public Health Laboratory, Department of Microbiology & Immunology at the Peter Doherty
14 Institute for Infection & Immunity, University of Melbourne, Melbourne, Victoria, Australia^f;
15 Victorian Infectious Disease Service, The Royal Melbourne Hospital, and The University of
16 Melbourne, at the Peter Doherty Institute for Infection & Immunity, University of Melbourne,
17 Melbourne, Victoria, Australia^g

18 **Running title:** Discrepant SXT resistance reporting of ST5 MRSA clone

19 **Corresponding Author:**

20 A/Prof Steven Tong

21 steven.tong@mh.org.au

22 Phone: +613 93429406 Fax: +613 93427277

23 Postal Address: 792 Elizabeth Street, Parkville, Victoria, Australia, 3000

24 Sir,

25 In regions where community-acquired methicillin-resistant *Staphylococcus aureus*
26 (MRSA) is common, oral trimethoprim sulfamethoxazole (SXT) is a treatment option for
27 skin and soft tissue infections. Recent trials have demonstrated non-inferiority of SXT in
28 comparison to intramuscular benzathine benzylpenicillin [1] or oral clindamycin [2] for
29 treatment of uncomplicated skin and soft tissue infections (SSTI) such as impetigo [1],
30 cellulitis, and simple abscesses [2]. Concern over the increasing rates of community-
31 acquired *S. aureus* isolates reported as SXT-resistant, has resulted in recommendations
32 against prescribing SXT for the treatment of SSTIs in the Kimberley region of Western
33 Australia [3].

34 During a clinical trial of SXT for treatment of impetigo in northern Australia (referred to
35 as the Skin Sore Trial) [1], 22/2211 *S. aureus* isolates (<1%), recovered from 8/508
36 children (1.6%) in the trial, were reported as SXT-resistant by Vitek®2 (bioMérieux,
37 France), using the Gram-positive AST-P612 card according to manufacturer's
38 instructions. To confirm SXT resistance, 19 of these isolates were tested for SXT and
39 trimethoprim resistance by Etest® (bioMérieux) according to manufacturer's
40 instructions. All 19 isolates were classed as trimethoprim-resistant but SXT-susceptible
41 by Etest® (Table 1). Two of these isolates were tested independently in a second
42 laboratory and also reported as SXT-resistant by Vitek®2, and trimethoprim-resistant
43 and SXT-susceptible by Etest® (Table 1). Repeat Vitek®2 testing using low thymidine
44 content subculture media did not change the results. These isolates were also
45 susceptible to SXT when tested using the Sensititre® broth microdilution
46 (ThermoScientific, United Kingdom) (Table 1).

47 Whole genome sequence analysis revealed that the 19 Skin Sore Trial isolates were all
48 sequence type (ST) 5 and harboured *lukS-PV* and *lukF-PV* (encoding for Panton-
49 Valentine leucocidin). Genome alignment to ST5 reference strain Mu50 demonstrated
50 that the isolates are a closely related clone, with a maximum of 15 orthologous single
51 nucleotide polymorphisms (SNPs) and three indels observed between any two isolates.

52 All 19 isolates harboured a novel SCCmec, consisting of a SCCmecIVc backbone, with a
53 putative *dfcG* mobile genetic element [4] located immediately upstream of IS431 in the
54 J3 region. This novel SCCmec construct has been assigned as SCCmecIVo by the
55 International Working Group on the Staphylococcal Cassette Chromosome Elements.
56 Consistent with the SXT-susceptible phenotype indicated by Etest® and Sensititre®, we
57 were unable to identify any acquired genes or mutations that potentially confer
58 sulfamethoxazole resistance (specifically the absence of acquired sulphonamide
59 resistance genes *sull*, *sulll* and *sullll*, and mutations in the chromosomal
60 dihydropteroate synthase gene *folP*).

61 The discrepancy between the Vitek®2, Etest®, and Sensititre® results was not restricted
62 to a specific clone or ST. An additional 12 clinical *S. aureus* isolates from a separate
63 study, including non-ST5 strains, reported as SXT-resistant by Vitek®2 (MIC 40 - ≥320
64 µg/mL) were reported SXT-susceptible by Etest® (MIC 0.023 - 2.0 µg/mL), and 10/12
65 isolates SXT-susceptible by Sensititre® (MIC ≤0.5 - 2 µg/mL).

66 Thus, we have identified a community-associated, trimethoprim- and methicillin-
67 resistant PVL-positive ST5 *S. aureus* clone circulating in the Northern Territory of
68 Australia. Isolates of this ST5 clone were collected from 2011-2013 from remote
69 communities in the Top End (coastal and inland tropical savannah) and Central
70 Australia (arid hot desert), and urban Darwin (coastal tropical) spanning a distance of

71 ~1,700km, indicating that this clone has successfully established itself. The emergence
72 of a PVL-positive, trimethoprim- and methicillin-resistant ST5 *S. aureus* clone was noted
73 in the Kimberley region of Western Australia in 2010, and now accounts for 9% of
74 MRSA infections in that region [5]. Given the phenotypic similarities, these ST5 clones
75 are likely related, but this has yet to be investigated.

76 The observed discrepancy in antimicrobial susceptibility testing results reported here is
77 concerning. Misleading results that over-call resistance may lead to unnecessary
78 restriction of effective oral treatment options for patients with *S. aureus* infections. In
79 remote Indigenous communities in northern Australia where there is a high burden of
80 staphylococcal infections and associated use of antibiotics, conditions are likely to be
81 conducive to selection for clones with resistance to β -lactams and other oral
82 antimicrobial agents. There has been clear evidence of the expansion of a ST5
83 trimethoprim-resistant clone in the neighbouring Kimberley region [5]. Whether SXT
84 should be used to treat skin sores in remote Australian communities is contentious,
85 with the principle question being whether the use of SXT will select SXT resistance.
86 Accordingly, overcalling of SXT resistance has great potential to lead to non-optimal
87 guidelines and practices.

88 Our findings are critical in demonstrating that the Northern Territory ST5 clone is not
89 SXT-resistant. The drivers of this clonal expansion are still to be determined, but are
90 unlikely to be related solely to the use of SXT. β -lactam use may be critical given the co-
91 location of *mecA* and *dfrG*. Ongoing surveillance of antimicrobial resistance among *S.*
92 *aureus* together with a more detailed understanding of the clinical significance of
93 trimethoprim resistance are now required.

95 TRANSPARENCY DECLARATION

96 The authors have no conflicts of interest.

97

98 FUNDING AND ACKNOWLEDGEMENTS

99 No external funding was received for this work. TMH is supported by a fellowship from
100 the Centre of Research Excellence in Respiratory Health of Aboriginal and Torres Strait
101 Islander children (Australian National Health and Medical Research Council (NHMRC)
102 award 1079557). AB and ST are supported by NHMRC fellowships (awards 1088738
103 and 1145033). DSS is supported by an Advance Queensland Fellowship (AQR13016-
104 17RD2). The authors thank Rachael Lilliebridge, Donna Woltring, Vanessa Rigas, Irene
105 O'Meara and Royal Darwin Hospital Laboratory scientists for technical assistance and
106 provision of isolates, and Savitra Rambococus at the Microbiological Diagnostic Unit
107 Public Health Laboratory, University of Melbourne, for technical assistance. We
108 acknowledge the participants in the Skin Sore Trial and the communities from which
109 they come, and Ross Andrews and Malcolm McDonald as among the original
110 investigators of the Skin Sore Trial.

111

112

113

114 REFERENCES

- 115 [1] A.C. Bowen, S.Y. Tong, R.M. Andrews, I.M. O'Meara, M.I. McDonald, M.D. Chatfield, B.J.
116 Currie, J.R. Carapetis, Short-course oral co-trimoxazole versus intramuscular benzathine
117 benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised,
118 controlled, non-inferiority trial. *Lancet* 2014;384(9960):2132-40.
- 119 [2] R.S. Daum, L.G. Miller, L. Immergluck, S. Fritz, C.B. Creech, D. Young, N. Kumar, M.
120 Downing, S. Pettibone, R. Hoagland, S.J. Eells, M.G. Boyle, T.C. Parker, H.F. Chambers, D.
121 Team, A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. *The New*
122 *England journal of medicine* 2017;376(26):2545-55.
- 123 [3] S.J. Oliver, J. Cush, J.E. Ward, Community-Based Prescribing for Impetigo in Remote
124 Australia: An Opportunity for Antimicrobial Stewardship. *Front Public Health*
125 2017;5:158.
- 126 [4] J-i. Sekiguchi, P. Tharavichitkul, T. Miyoshi-Akiyama, V. Chupia, T. Fujino, M. Araake,
127 A. Irie, K. Morita, T. Kuratsuji, T. Kirikae, Cloning and Characterization of a Novel
128 Trimethoprim-Resistant Dihydrofolate Reductase from a Nosocomial Isolate of
129 *Staphylococcus aureus* CM.S2 (IMCJ1454). *Antimicrobial Agents and Chemotherapy*
130 2005;49(9):3948-51.
- 131 [5] G.W. Coombs, J. Pearson, O. Robinson, Western Australian Methicillin-Resistant
132 *Staphylococcus aureus* (MRSA) Epidemiology and Typing Report - July 1 2015 to June 30
133 2016, Western Australia, 2017.

Table 1 Skin Sore Trial isolates

Isolate ^a	MIC ($\mu\text{g}/\text{mL}$)			ST	SCC _{mec}	<i>dfrG</i>	Lab 2 MIC ($\mu\text{g}/\text{mL}$)			
	Vitek [®] 2	Etest [®]					Vitek [®] 2	Etest [®]		BMD ^e
	SXT ^b	TMP ^c	SXT ^d				SXT	TMP	SXT	SXT
SST1502_S1A_SA1	320 (16/304)	≥ 32	0.25	5	IVo	+				
SST1502_S2A_SA1	320 (16/304)	≥ 32	0.25	5	IVo	+				
SST1502_S3A_SA1	320 (16/304)	≥ 32	0.25	5	IVo	+	160 (8/152)	>32	0.125	2
SST1505_NS2_SA1	320 (16/304)	≥ 32	0.25	5	IVo	+				
SST2254_S1B_SA1	320 (16/304)	≥ 32	0.25	5	IVo	+				
SST2272_S2B_SA1	320 (16/304)	≥ 32	0.25	5	IVo	+				
SST2272_S3B_SA1	320 (16/304)	≥ 32	0.25	5	IVo	+				
SST2281_S1B_SA1	320 (16/304)	≥ 32	0.25	5	IVo	+				

SST2281_S2B_SA1	320 (16/304)	≥32	0.25	5	IVo	+			
SST2287_S1A_SA1	320 (16/304)	≥32	0.25	5	IVo	+			
SST2287_S1B_SA1	320 (16/304)	≥32	0.25	5	IVo	+			
SST2287_S2A_SA1	320 (16/304)	≥32	0.25	5	IVo	+			
SST2287_S2B_SA1	320 (16/304)	≥32	0.25	5	IVo	+			
SST2352_S1B_SA1	320 (16/304)	≥32	0.25	5	IVo	+			
SST2352_S1B_SA2	320 (16/304)	≥32	0.25	5	IVo	+			
SST2352_S2A_SA1	320 (16/304)	≥32	0.25	5	IVo	+			
SST2352_NS2_SA1	320 (16/304)	≥32	0.25	5	IVo	+			
SST2352_NS2_SA2	320 (16/304)	≥32	0.25	5	IVo	+	320 (16/304)	>32	0.125 1
SST2352_NS2_SA3	320 (16/304)	≥32	0.25	5	IVo	+			

^a The first four numbers following 'SST' denote the study ID of the Skin Sore Trial participant from which the isolate was derived.

^b Vitek[®]2 trimethoprim-sulfamethoxazole (SXT) MICs are reported as the sum of the trimethoprim and sulfamethoxazole MICs which are present in a ratio of 1:19. The SXT resistance breakpoint in this system is ≥ 80 mg/L (CLSI).

^c TMP, trimethoprim. The EUCAST trimethoprim resistance breakpoint is >4 $\mu\text{g/mL}$.

^d Etest[®] SXT MICs are reported as the trimethoprim MIC in $\mu\text{g/mL}$. The EUCAST SXT resistance breakpoint is >4 $\mu\text{g/mL}$.

^e Broth microdilution (BMD) SXT MICs are reported as the trimethoprim MIC in $\mu\text{g/mL}$. The resistance breakpoint for this system is ≥ 4 $\mu\text{g/mL}$.